VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer

American Journal of Clinical Pathology

Volumn 128, Issue 5, 2007, Pages 759-766

  Van Iterson, Vincent ^a   Leidenius, Marjut ^a   Von Smitten, Karl ^a   Bono, Petri ^a   Heikkilä, Päivi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Breast; Breast cancer; Growth factor; Immunohistochemistry; Lymphangiogenesis; Metastasis

Indexed keywords

LYMPHATIC VESSEL ENDOTHELIAL RECEPTOR 1; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; ENDOTHELIAL CELLS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 36249027630     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/7FXVRMXF58PVRJUH     Document Type: Article

References (34)

1. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45:2917-2924.
2. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989;7:1239-1251.
3. Mansour EG, Ravdin PM, Dressier L. Prognostic factors in early breast carcinoma. Cancer. 1994;74:381-400.
4. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg. 2001;25:767-772.
5. Martin C, Cutuli B, Velten M. Predictive model of axillary lymph node involvement in women with small invasive breast carcinoma: axillary metastases in breast carcinoma. Cancer. 2002;94:314-322.
6. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573-583.
7. Pepper MS, Tille JC, Nisato R, et al. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003;314:167-177.
8. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
9. Prevo R, Banerji S, Ferguson DJ, et al. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem. 2001;276:19420-19430.
10. Baldwin ME, Stacker SA, Achen MG. Molecular control of lymphangiogenesis. Bioessays. 2002;24:1030-1040.
11. Saharinen P, Petrova TV. Molecular regulation of lymphangiogenesis. Ann N Y Acad Sci. 2004;1014:76-87.
12. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases [published correction for EMBO J. 1996;15:290-298]. EMBO J. 1996;15:1751.
13. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548-553.
14. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92:3566-3570.
15. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999;86:2406-2412.
16. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol. 2003;16:309-314.
17. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat. 2005;91:125-132.
18. Kinoshita J, Kitamura K, Kabashima A, et al. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat. 2001;66:159-164.
19. Watanabe O, Kinoshita J, Shimizu T, et al. Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res. 2005;24:75-82.
20. Yang W, Klos K, Yang Y, et al. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 2002;94:2855-2861.
21. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin Cancer Res. 2003;9:716-721.
22. Currie MJ, Hanrahan V, Gunningham SP, et al. Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol. 2004;57:829-834.
23. Krogerus LA, Leidenius MH, Toivonen TS, et al. Towards reasonable workload in diagnosis of sentinel lymph nodes: comparison of two frozen section methods. Histopathology. 2004;44:29-34.
24. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
25. Bono P, Wasenius VM, Heikkila P, et al. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res. 2004;10:7144-7149.
26. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol. 2003;200:195-206.
27. Li CI, Anderson BO, Porter P, et al. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88:2561-2569.
28. Dixon AR, Ellis IO, Elston CW, et al. A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer. 1991;63:634-635.
29. Harris M, Howell A, Chrissohou M, et al. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50:23-30.
30. Bussolati G, Gugliotta P, Morra I, et al. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer. 1986;54:631-636.
31. de Mascarel I, Soubeyran I, MacGrogan G, et al. Immunohistochemically detected lymph node metastases from breast carcinoma: practical considerations about the new American Joint Committee on Cancer classification. Cancer. 2005;103:1319-1322.
32. Leidenius M, Krogerus L, Tukiainen E, et al. Accuracy of axillary staging using sentinel node biopsy or diagnostic axillary lymph node dissection: a case-control study. APMIS. 2004;112:264-270.
33. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381-1390.
34. Longatto Filho A, Martins A, Costa SM, et al. VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract. 2005;201:93-99.